Latest News

Phase 2B ExTINGUISH Trial Aims to Assess Efficacy of Inebilizumab for NMDAR Encephalitis
Phase 2B ExTINGUISH Trial Aims to Assess Efficacy of Inebilizumab for NMDAR Encephalitis

June 17th 2025

The ExTINGUISH trial investigates inebilizumab's efficacy for NMDAR encephalitis, aiming to enhance treatment options for diverse patient populations.

Mendelian Randomization Analysis Identifies Neuroprotective and At-Risk Proteins for NMOSD
Mendelian Randomization Analysis Identifies Neuroprotective and At-Risk Proteins for NMOSD

June 17th 2025

Anti-Alpha-Synuclein Antibody Prasinezumab Enters Phase 3 Development
Anti-Alpha-Synuclein Antibody Prasinezumab Enters Phase 3 Development

June 17th 2025

Emerging Pharmacotherapies Offer New Hope in Obstructive Sleep Apnea Treatment
Emerging Pharmacotherapies Offer New Hope in Obstructive Sleep Apnea Treatment

June 16th 2025

12-Month Extension Data Highlights Ecopipam as an Effective Option for Tourette Syndrome
12-Month Extension Data Highlights Ecopipam as an Effective Option for Tourette Syndrome

June 16th 2025

Coverage of SLEEP 2025

Get direct access to interviews with experts, straight from the conference floor in Seattle, as well as the latest data and clinical news updates.

SLEEP 2025

Conference Coverage

View All
Sam Hooshmand, DO
Challenges and Considerations in the Care Management of Advanced Stages of Multiple Sclerosis: Sam Hooshmand, DO

June 17th 2025

Bridging Sleep Science and Biomarkers in Neurodegeneration: Lea Grinberg, MD, PhD
Bridging Sleep Science and Biomarkers in Neurodegeneration: Lea Grinberg, MD, PhD

June 17th 2025

Funke Afolabi-Brown, MD, FAASM
Using a Family-Centered Approach for Care in Pediatric Sleep Health: Funke Afolabi-Brown, MD, FAASM

June 17th 2025

Emerging Pharmacotherapies Offer New Hope in Obstructive Sleep Apnea Treatment
Emerging Pharmacotherapies Offer New Hope in Obstructive Sleep Apnea Treatment

June 16th 2025

Video Series
Video Interviews
Podcasts

Most Recent

© 2025 MJH Life Sciences

All rights reserved.